Evaluation of Safety, Efficacy and Thermogenesis-induction of RZL-012 in Overweight and Obese Volunteers
Status:
Completed
Trial end date:
2018-12-28
Target enrollment:
Participant gender:
Summary
Obesity is a direct result of food-intake in excess of body energy expenditure. Thus,
induction of increased energy expenditure via the activation of thermogenesis at targeted
anatomical sites can counterbalance obesity. This trial aims to study RZL-012, a novel
compound, in treating obesity by activating thermogenesis in subcutaneous fat.